Joao J. Oliveira
Cambridge, ENG, United Kingdom
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 9 publications
A randomised, single-blind, placebo-controlled, dose-finding safety and tolerability study of the anti-CD3 monoclonal antibody otelixizumab in new-onset type 1 diabetes.
Journal: Diabetologia
Published: May 14, 2020
Chronic Immune Activation in Systemic Lupus Erythematosus and the Autoimmune PTPN22 Trp620 Risk Allele Drive the Expansion of FOXP3+ Regulatory T Cells and PD-1 Expression.
Journal: Frontiers in immunology
Published: June 20, 2019
The plasma biomarker soluble SIGLEC-1 is associated with the type I interferon transcriptional signature, ethnic background and renal disease in systemic lupus erythematosus.
Journal: Arthritis research & therapy
Published: February 16, 2018
Capturing the systemic immune signature of a norovirus infection: an n-of-1 case study within a clinical trial.
Journal: Wellcome open research
Published: August 18, 2017
Cells with Treg-specific FOXP3 demethylation but low CD25 are prevalent in autoimmunity.
Journal: Journal of autoimmunity
Published: May 16, 2017
Human IL-6RhiTIGIT- CD4+CD127lowCD25+ T cells display potent in vitro suppressive capacity and a distinct Th17 profile.
Journal: Clinical immunology (Orlando, Fla.)
Published: December 02, 2016
CCL20 neutralization by a monoclonal antibody in healthy subjects selectively inhibits recruitment of CCR6+ cells in an experimental suction blister.
Journal: British journal of clinical pharmacology
Published: August 11, 2016
Characterisation of the clinical and activated T cell response to repeat delayed-type hypersensitivity skin challenges in human subjects, with KLH and PPD, as a potential model to test T cell-targeted therapies.
Journal: Inflammation research : official journal of the European Histamine Research Society ... [et al.]
Published: May 26, 2015
Showing 1-9 of 9
Last Updated: 09/26/2026